Voyager Therapeutics doses first participants in Phase 1a trial of anti-tau antibody VY-TAU01 for Alzheimer's

Voyager Therapeutics, Inc.

First participants dosed in Phase 1a SAD trial of VY-TAU01, an anti-tau antibody for Alzheimer's disease.
Trial is randomized, double-blind, placebo-controlled, evaluating safety and PK in healthy adult volunteers.
Study conducted at a single U.S. site; expected to enroll approximately 48 patients across multiple cohorts.
VY-TAU01 designed to inhibit spread of pathological tau in Alzheimer's disease.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.